Company achieves mid-year goal of more than 1,000 genes in production
Hosting an investor call today at 4:30 p.m. ET
Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and expanded panels for neurology, pediatrics, and rare diseases. Invitae also has introduced an entirely new clinical testing area designed to complement newborn screening for metabolic and immunological conditions.
With this expanded test menu ...